Lepodisiran, a Small Intefering RNA, Could Lower Lp(a) by Mo

Presented at AHA 2023, phase 1 data for lepodisiran showcased a 97% reduction in lipoprotein(a) levels at the 608 mg dose.

Related Keywords

Singapore , United States , American , Eli Lilly , Steve Nissen , American Heart Association Scientific Sessions , Heart Vascular Thoracic Institute At Cleveland Clinic , Heart Vascular , Thoracic Institute , Cleveland Clinic , Standard Deviation , Interquartile Range ,